Dr. Michael Pishvaian is an Assistant Professor in Hematology/Oncology at the Lombardi Comprehensive Cancer Center, Georgetown University. He is also the Director of the Phase I Clinical Trial Program at Lombardi. Dr. Pishvaian is an MD and a PhD in Tumor Biology, and earned both degrees at Georgetown. He completed both his medical residency and his fellowship in Hematology/Oncology at Georgetown, before joining the faculty in Lombardi. Dr. Pishvaian is a Gastro-intestinal oncologist focused on translational cancer care. His background as an MD and a PhD has put him in a unique position to understand the basic science of targeted therapies in oncology, while providing him with the training as a compassionate clinical oncologist. His area of focus is the development of rational combinations of novel, targeted anti-cancer agents, with a particular emphasis on pancreatic cancer, and refractory colorectal cancer. Dr. Pishvaian is Principal Investigator on several clinical trials, including Phase I trials, and Phase II trials for patients with colorectal and pancreatic cancer. Each of Dr. Pishvaian’s trials are heavily focused on the acquisition and analysis of patient tumor biopsies to identify molecular markers that are predictive of response to therapy. As Chief Medical Officer for Personalized Cancer Therapy, Inc, Dr. Pishvaian chairs the medical review panel and is directly involved in the analysis and review for each patient. He also applies his expertise as a translational oncologist and experience in running clinical trials toward Perthera's ongoing development and expansion of optimal tissue handling procedures and the advanced expert system for precise therapy matching to patients and clinical trial screening.